Arrowhead Pharmaceuticals Inc Analyst and Investor Event on Plozasiran and Zodasiran (Virtual) Transcript
Good afternoon, and welcome to the Arrowhead Pharmaceuticals' Virtual Analyst and Investor Event. (Operator Instructions). As a reminder, this call is being recorded and the replay will be available on the Arrowhead website following the conclusion of the event.
I'd now like to turn the call over to Vince Anzalone of Arrowhead Pharmaceuticals. Please go ahead, Vince.
Thank you, Tara, and thanks, everybody, for joining us today. We've got a lot to cover. We presented data at AHA on 3 of the studies for 2 of our cardiometabolic programs for plozasiran, formerly known as ARO-APOC3, and zodasiran, formerly ARO-ANG3.
So before we start, I just want to let you know that we will be making forward-looking statements, so please refer to our SEC filings for risks.
And we've got a really great panel today -- sorry, let me get to that slide. Sorry. We have Dr. Daniel Gaudet from the University of Montreal, Børge Nordestgaard from University of Copenhagen and Dr. Steven
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |